Conditional BDNF release under pathological conditions improves Huntington's disease pathology by delaying neuronal dysfunction
<p>Abstract</p> <p>Background</p> <p>Brain-Derived Neurotrophic Factor (BDNF) is the main candidate for neuroprotective therapy for Huntington's disease (HD), but its conditional administration is one of its most challenging problems.</p> <p>Results<...
Main Authors: | Lao-Peregrin Cristina, Carretón Olga, Giralt Albert, Martín Eduardo D, Alberch Jordi |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2011-10-01
|
Series: | Molecular Neurodegeneration |
Subjects: | |
Online Access: | http://www.molecularneurodegeneration.com/content/6/1/71 |
Similar Items
-
Prostaglandin E2 EP2 activation reduces memory decline in R6/1 mouse model of Huntington's disease by the induction of BDNF-dependent synaptic plasticity
by: Marta Anglada-Huguet, et al.
Published: (2016-11-01) -
The contribution of glial cells to Huntington's disease pathogenesis
by: Daniel K. Wilton, et al.
Published: (2020-09-01) -
Reduced Fractalkine Levels Lead to Striatal Synaptic Plasticity Deficits in Huntington’s Disease
by: Anya Kim, et al.
Published: (2020-06-01) -
Alleviation of Huntington pathology in mice by oral administration of food additive glyceryl tribenzoate
by: Debashis Dutta, et al.
Published: (2021-06-01) -
Excess Rab4 rescues synaptic and behavioral dysfunction caused by defective HTT-Rab4 axonal transport in Huntington’s disease
by: Joseph A. White, et al.
Published: (2020-07-01)